Amanda Rowlands
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amanda Rowlands has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Abdulsalam Abu-Libdeh
Global Pediatric Endocrinology and Diabetes, Vancouver, British Columbia, Canada
1 shared publication - Andrew Gibbs
University of KwaZulu‐Natal KwaZulu‐Natal South Africa
1 shared publication - Angela Kaida
Simon Fraser University, Burnaby, Canada
1 shared publication - Asma Deeb
Paediatric Endocrine Division, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates
1 shared publication - Asmahane Ladjouze
Faculty of Medicine University of health science, Department of Paediatrics, Beni Messous teaching hospital, Algiers, Algeria, Algeria
1 shared publication - Campion Zharima
University of the Witwatersrand
1 shared publication
Latest Publications
- 20 July 2026
- Published by Taylor & Francis in Culture, Health & Sexuality
- p. 1-14
Perceptions of masculinity and relationship power among young men in Durban and Soweto, South Africa
Gender is widely recognised as a determinant of health, shaping health outcomes through biological, behavioural, psychosocial and structural pathways (Bambra, Albani, and Franklin 2021; Lyons 2009;...
- 20 July 2026
- Published by Taylor & Francis in Culture, Health & Sexuality
- p. 1-14
Perceptions of masculinity and relationship power among young men in Durban and Soweto, South Africa
Gender is widely recognised as a determinant of health, shaping health outcomes through biological, behavioural, psychosocial and structural pathways (Bambra, Albani, and Franklin 2021; Lyons 2009;...
- Open Access
- 21 October 2021
- Published by BMJ in BMJ Global Health
- Vol. 6 (10) , e007195
Access to fludrocortisone and to hydrocortisone in children with congenital adrenal hyperplasia in the WHO Eastern Mediterranean Region: it takes a village…
Congenital adrenal hyperplasia (CAH), if untreated, carries high morbidity and mortality. A higher incidence of CAH is expected in countries where consanguinity is common, such as in the countries of the WHO Eastern Mediterranean Region (EMRO). CAH is managed through lifelong treatment with fludrocortisone and hydrocortisone. In this analysis, performed in the 22 EMRO countries and territories plus Algeria, we review which countries offer a neonatal screening programme for CAH and describe the barriers and opportunities to access oral fludrocortisone and oral and injectable hydrocortisone. Neonatal CAH screening was only available nationally in Qatar, Kuwait and partially in Lebanon and Saudi Arabia. We reviewed the national lists of essential medicines (NEMLs) and found that 13/23 (57%) countries included fludrocortisone and 18/23 (78%) included oral hydrocortisone. Fludrocortisone was not included by any of the low-income countries and oral hydrocortisone was only included by one low-income country. We then contacted paediatric endocrinologists in each country to assess perceived availability of these medicines. Overall, there was a relatively good consistency between inclusion of fludrocortisone and hydrocortisone in the NEML and their actual availability in a country. We propose several mechanisms to improve access, including prequalification by the WHO, a common registration process for groups of countries, pooled procurement, working with local pharmaceutical companies, special access status for medicines not yet registered in a country and compounding. We suggest that access to medicines requires a collaboration between health professionals, families of patients, health authorities, pharmaceutical companies and the WHO.
- 21 October 2021
- Published by BMJ in BMJ Global Health
- Vol. 6 (10) , e007195
Open AccessAccess to fludrocortisone and to hydrocortisone in children with congenital adrenal hyperplasia in the WHO Eastern Mediterranean Region: it takes a village…
Congenital adrenal hyperplasia (CAH), if untreated, carries high morbidity and mortality. A higher incidence of CAH is expected in countries where consanguinity is common, such as in the countries of the WHO Eastern Mediterranean Region (EMRO). CAH is managed through lifelong treatment with fludrocortisone and hydrocortisone. In this analysis, performed in the 22 EMRO countries and territories plus Algeria, we review which countries offer a neonatal screening programme for CAH and describe the barriers and opportunities to access oral fludrocortisone and oral and injectable hydrocortisone. Neonatal CAH screening was only available nationally in Qatar, Kuwait and partially in Lebanon and Saudi Arabia. We reviewed the national lists of essential medicines (NEMLs) and found that 13/23 (57%) countries included fludrocortisone and 18/23 (78%) included oral hydrocortisone. Fludrocortisone was not included by any of the low-income countries and oral hydrocortisone was only included by one low-income country. We then contacted paediatric endocrinologists in each country to assess perceived availability of these medicines. Overall, there was a relatively good consistency between inclusion of fludrocortisone and hydrocortisone in the NEML and their actual availability in a country. We propose several mechanisms to improve access, including prequalification by the WHO, a common registration process for groups of countries, pooled procurement, working with local pharmaceutical companies, special access status for medicines not yet registered in a country and compounding. We suggest that access to medicines requires a collaboration between health professionals, families of patients, health authorities, pharmaceutical companies and the WHO.